Publication Name	World Journal of Hepatology
Manuscript ID	7151
Country	China

Received	2013-11-06 10:19
Peer-Review Started	2013-11-06 17:29
To Make the First Decision	2013-12-25 18:19
Return for Revision	2014-01-06 09:25
Revised
Second Decision	2014-04-16 15:59
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-04-16 16:06
Articles in Press	2014-05-23 12:24
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-05-09 07:23
Typeset the Manuscript	2014-07-01 12:13
Publish the Manuscript Online	2014-07-04 18:01

ISSN	1948-5182 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Management of hepatitis C virus infection in hemodialysis patients
Manuscript Source	Invited Manuscript
All Author List	Yue-Cheng Yu, Yue Wang, Chang-Lun He, Mao-Rong Wang and Yu-Ming Wang
Funding Agency and Grant Number
Corresponding Author	Yue Wang, MD, PhD, Professor, National Institute for Viral Disease Control and Prevention, Chinese Center for Diseases Control and Prevention, Xicheng District, Yingxin Rd, Beijing 100052, China. euy-tokyo@umin.ac.jp
Key Words	Hemodialysis; Hepatitis C virus; Epidemiology; Risk factors; Prophylaxis; Treatment
Core Tip	The new hepatitis C virus (HCV) infections during maintenance hemodialysis (MHD) in recent years are mainly caused by the lack of stringent universal precautions. Strict implementation of universal precautions for HCV transmission has led to markedly decreased HCV infections in many hemodialysis units, but the anti-HCV negative HCV infection and occult HCV infection in MHD patients still should be noted. How to increase the sustained virological response and decrease the side effects is the key problem for the currently recommended IFNα-based antiviral therapy in MHD patients. IFNα-free treatments with two or three direct-acting antivirals without RBV in MHD patients are waiting for future investigations.
Publish Date	2014-07-04 18:01
Citation	Yu YC, Wang Y, He CL, Wang MR, Wang YM. Management of hepatitis C virus infection in hemodialysis patients. World J Hepatol 2014; 6(6): 419-425
URL	http://www.wjgnet.com/1948-5182/full/v6/i6/419.htm
DOI	http://dx.doi.org/10.4254/wjh.v6.i6.419

Full Article (PDF)	WJH-6-419.pdf
Full Article (Word)	WJH-6-419.doc
Manuscript File	7151-Review.doc
Answering Reviewers	7151-Answering reviewers.pdf
Copyright License Agreement	7151-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	7151-Language certificate.pdf
Peer-review Report	7151-Peer review(s).pdf
Scientific Editor Work List	7151-Scientific editor work list.doc